PE20100372A1 - Inhibidores de la s1p liasa para el tratamiento de malaria cerebral - Google Patents
Inhibidores de la s1p liasa para el tratamiento de malaria cerebralInfo
- Publication number
- PE20100372A1 PE20100372A1 PE2009001211A PE2009001211A PE20100372A1 PE 20100372 A1 PE20100372 A1 PE 20100372A1 PE 2009001211 A PE2009001211 A PE 2009001211A PE 2009001211 A PE2009001211 A PE 2009001211A PE 20100372 A1 PE20100372 A1 PE 20100372A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- cerebral malaria
- liasa
- inhibitors
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE CONTIENE: A) UN INHIBIDOR DE LA ESFINGOSINA-1-FOSFATO (S1P) LIASA TAL COMO LOS COMPUESTOS DE FORMULA (I) DONDE R1 ES H, ALQUILO(C1-C20) O ARILO; R3 ES H, OR3A, NHC(O)R3A, ENTRE OTROS, DONDE R3A ES H, ALQUILO(C1-C20), ENTRE OTROS; R6 ES OR6A U OC(O)R6A; R7 ES OR7A U OC(O)R7A; R8 ES OR8A U OC(O)R8A; R9 ES H, CH2OR9A O CH2OC(O)R9A, EN DONDE R6A, R7A, R8A Y R9A SON H O ALQUILO INFERIOR(C1-C4); SIENDO UN COMPUESTO PREFERIDO (E)-1-(4-((1R,2S,3R)-1,2,3,4-TETRAHIDROXIBUTIL)-1H-IMIDAZOL-2-IL)-ETANONA OXIMA; Y B) UN AGENTE ACTIVO SELECCIONADO ENTRE i) UN FARMACO ANTI MALARIA TAL COMO QUININA, QUINIDINA, ENTRE OTROS, ii) UN DIURETICO OSMOTICO TAL COMO MANITOL O UREA, iii) UN ANTI CONVULSIVANTE TAL COMO DIAZEPAN, FENITOINA, ENTRE OTROS, iv) UN ANTIPIRETICO TAL COMO PARACETAMOL, v) UN ANTIOXIDANTE, O vi) UN ANTIINFLAMATORIO TAL COMO UN AINE, INFLIXIMAB, ENTRE OTROS. DICHA COMPOSICION ES UTIL PARA TRATAR, MANEJAR Y/O PREVENIR LA MALARIA CEREBRAL
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10998208P | 2008-10-31 | 2008-10-31 | |
| US10998708P | 2008-10-31 | 2008-10-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20100372A1 true PE20100372A1 (es) | 2010-06-01 |
Family
ID=41480156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2009001211A PE20100372A1 (es) | 2008-10-31 | 2009-10-28 | Inhibidores de la s1p liasa para el tratamiento de malaria cerebral |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20100113530A1 (es) |
| EP (1) | EP2367551A1 (es) |
| JP (1) | JP2012507547A (es) |
| CN (1) | CN102196808A (es) |
| AR (1) | AR074061A1 (es) |
| AU (1) | AU2009308832A1 (es) |
| CA (1) | CA2741838A1 (es) |
| CL (1) | CL2009002018A1 (es) |
| PE (1) | PE20100372A1 (es) |
| TW (1) | TW201022254A (es) |
| UY (1) | UY32215A (es) |
| WO (1) | WO2010051353A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3782702A1 (en) * | 2019-08-21 | 2021-02-24 | AC BioScience SA | Compounds and use thereof for the treatment of infectious diseases and cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1260155B (it) * | 1992-08-03 | 1996-03-28 | Fidia Spa | Uso terapeutico della fosforil-l-serina-n-acil-sfingosina |
| US7649098B2 (en) * | 2006-02-24 | 2010-01-19 | Lexicon Pharmaceuticals, Inc. | Imidazole-based compounds, compositions comprising them and methods of their use |
| MX2009006304A (es) * | 2006-12-15 | 2009-06-23 | Abbott Lab | Nuevos compuestos de oxadiazol. |
| EP2120575A4 (en) * | 2006-12-21 | 2011-04-27 | Abbott Lab | AGONISTS AND ANTAGONISTS OF SPHINGOSINE-1-PHOSPHATE RECEPTORS |
| WO2008124210A1 (en) * | 2007-02-14 | 2008-10-16 | Emory University | Methods and compositions for treating or preventing infection using leukocyte sequestration agents |
| TW200848029A (en) * | 2007-03-01 | 2008-12-16 | Lexicon Pharmaceuticals Inc | Heterocyclic compounds, compositions comprising them and methods of their use |
-
2009
- 2009-10-27 AR ARP090104142A patent/AR074061A1/es unknown
- 2009-10-28 PE PE2009001211A patent/PE20100372A1/es not_active Application Discontinuation
- 2009-10-28 TW TW098136567A patent/TW201022254A/zh unknown
- 2009-10-29 JP JP2011534749A patent/JP2012507547A/ja active Pending
- 2009-10-29 CA CA2741838A patent/CA2741838A1/en not_active Abandoned
- 2009-10-29 AU AU2009308832A patent/AU2009308832A1/en not_active Abandoned
- 2009-10-29 CN CN200980142976XA patent/CN102196808A/zh active Pending
- 2009-10-29 EP EP09744573A patent/EP2367551A1/en not_active Withdrawn
- 2009-10-29 US US12/608,426 patent/US20100113530A1/en not_active Abandoned
- 2009-10-29 WO PCT/US2009/062511 patent/WO2010051353A1/en active Application Filing
- 2009-10-30 UY UY0001032215A patent/UY32215A/es not_active Application Discontinuation
- 2009-10-30 CL CL2009002018A patent/CL2009002018A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN102196808A (zh) | 2011-09-21 |
| EP2367551A1 (en) | 2011-09-28 |
| AU2009308832A1 (en) | 2010-05-06 |
| AR074061A1 (es) | 2010-12-22 |
| WO2010051353A1 (en) | 2010-05-06 |
| JP2012507547A (ja) | 2012-03-29 |
| CA2741838A1 (en) | 2010-05-06 |
| TW201022254A (en) | 2010-06-16 |
| US20100113530A1 (en) | 2010-05-06 |
| UY32215A (es) | 2010-05-31 |
| CL2009002018A1 (es) | 2010-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP11011014A (es) | Compuestos de pirazolopirimidina inhibidores de jak y métodos | |
| JP5160409B2 (ja) | 外用の医薬組成物 | |
| ECSP078003A (es) | Inhibidores de aspartil proteasas | |
| AR067495A1 (es) | Composiciones farmaceuticas y procedimientode tratamientos de trastornos de ojo seco | |
| CO6470846A2 (es) | Derivados aminobut´ricos sustituidos como inhibidores de neprilisina | |
| ECSP11011560A (es) | Derivados amino-propiónicos sustituidos como inhibidores de neprilisina | |
| MX356032B (es) | Compuestos indola y métodos para tratar el dolor visceral. | |
| CU20150084A7 (es) | Derivados del ácido 4-((1,1) bisfenil -4-il)-3-(3-fosfonopropanamido)butanoico,activo como inhibidores de nep(endopeptidasa neutral) | |
| MX2010008818A (es) | Derivado de bicicloamina. | |
| RU2008135979A (ru) | Соединения гидроксиакрилаимда | |
| PE20100371A1 (es) | Agonistas del receptor s1p para el tratamiento de malaria cerebral | |
| MX2011008910A (es) | Derivados de azol sustituidos, composicion farmaceutica que comprende los derivados, y uso de los derivados para tratar enfermeda de parkinson. | |
| DOP2009000106A (es) | Compuestos de pirazol y triazol sustituídos como inhibidores de ksp | |
| EA201071395A1 (ru) | Ингибитор толерантности к анальгетику | |
| JP2008534541A5 (es) | ||
| AR119318A1 (es) | Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1 | |
| PE20212323A1 (es) | Formulaciones farmaceuticas | |
| ES2582660T3 (es) | Sidnoniminas - inhibidores específicos de la recaptación de la dopamina y su uso en el tratamiento de los trastornos relacionados con la dopamina | |
| PE20100372A1 (es) | Inhibidores de la s1p liasa para el tratamiento de malaria cerebral | |
| CU20190028A7 (es) | Compuestos de indazol útiles en lesiones de tendones y/o ligamentos | |
| UY33332A (es) | Compuestos de triazol como inhibidores de ksp | |
| AR082022A1 (es) | Agente terapeutico de liberacion sostenida para la hipertension y la disfuncion renal | |
| RU2014119919A (ru) | Способ лечения капиллярных гемангиом | |
| MX2020008230A (es) | Derivados de ester butanoico sustituido con bisfenilo como inhibidores de nep. | |
| DOP2023000205A (es) | Nuevos moduladores de nr2b alostéricos negativos de ciclopenta[c]pirrol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |